These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17160632)

  • 1. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Wei M; Taskapan H; Esbaei K; Jassal SV; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2006; 38(3-4):739-43. PubMed ID: 17160632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
    Deger SM; Mutluay R; Derici U; Mandiralioglu F; Arinsoy T; Sindel S
    Med Princ Pract; 2011; 20(1):85-9. PubMed ID: 21160221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study.
    Janjua TK; Mukhtar KN; Naveed AK; Ahmed EB; Rehan M
    Pan Afr Med J; 2019; 33():183. PubMed ID: 31565143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
    Al Aly Z; González EA; Martin KJ; Gellens ME
    Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W; Chaiyakum A; Pongskul C
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of bone mineral metabolism derangements by K/DOQI guidelines in haemodialysis patients at Rawalpindi.
    Khan DA; Fatima-Tuz-Zuhra ; Khan FA; Saif I
    J Pak Med Assoc; 2009 Feb; 59(2):64-7. PubMed ID: 19260564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline.
    Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA
    Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations.
    Labriola L; Wallemacq P; Gulbis B; Jadoul M
    Nephrol Dial Transplant; 2009 Jun; 24(6):1834-8. PubMed ID: 19182240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
    Cozzolino M; Messa P; Brancaccio D; Cannella G; Bolasco P; Di Luca M; Costanzo AM; Paparatti Ud; Festa V; Gualberti G; Mazzaferro S;
    Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
    Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.